Peripheral Androgen Blockade Feasible for PSA Relapse

Share this article:

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.

In a study, 99 such patients received finasteride 5 mg orally per day and flutamide 250 mg orally three times a day. Investigators observed an 80% or greater decline in PSA in 96 patients (96%). Five-year overall survival was 87%. Toxicities were mild.

The researchers, led by J. Paul Monk, MD, of The Ohio State University School of Medicine in Columbus, noted that “because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Male Pattern Baldness Linked with Prostate Cancer

Male Pattern Baldness Linked with Prostate Cancer

Men with male pattern baldness may face a higher risk of aggressive prostate cancer.

Statins Reduce Prostate Cancer Recurrence Risk After Radiotherapy

Statins Reduce Prostate Cancer Recurrence Risk After Radiotherapy

This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.

Watchful Waiting Not Suitable for Black Men with Prostate Cancer

Watchful Waiting Not Suitable for Black Men with ...

Black prostate cancer patients more likely to develop aggressive disease earlier than white patients.